Origin of tuberculosis in the Paleolithic predicts unprecedented population growth and female resistance.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 01 2020
Historique:
received: 12 10 2019
accepted: 09 12 2019
entrez: 9 1 2020
pubmed: 9 1 2020
medline: 20 11 2020
Statut: epublish

Résumé

Current data estimate the origin of Mycobacterium tuberculosis complex (MtbC) infection around 73,000 years before the common era (BCE), and its evolution to "modern" lineages around 46,000 BCE. Being MtbC a major killer of humanity, the question is how both species could persist. To answer this question, we have developed two new epidemiological models (SEIR type), adapted to sex dimorphism and comparing coinfection and superinfection for different MtbC lineages. We have attributed a higher resistance/tolerance to females to explain the lower incidence noted in this sex, a better health status in the Paleolithic compared to the Neolithic, and a higher dissemination of "modern" lineages compared to "ancient" ones. Our findings show the extraordinary impact caused by "modern" lineages, provoking the extinction of the groups infected. This could only be overcomed by an unprecedented population increase (x20 times in 100 years) and helped with the protection generated by previous infection with "ancient" lineages. Our findings also suggest a key role of female resistance against MtbC. This data obliges us to rethink the growth population parameters in the Paleolithic, which is crucial to understanding the survival of both MtbC and humans, and to decipher the nature of human female resistance against TB.

Identifiants

pubmed: 31913313
doi: 10.1038/s41598-019-56769-1
pii: 10.1038/s41598-019-56769-1
pmc: PMC6949267
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

42

Références

Evolution. 2004 Aug;58(8):1685-95
pubmed: 15446423
PLoS One. 2014 Aug 26;9(8):e105721
pubmed: 25157958
Bull Int Union Tuberc. 1969 Aug;42:1-104
pubmed: 5004883
N Engl J Med. 2018 Oct 25;379(17):1672-1674
pubmed: 30252629
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
PLoS Med. 2016 Sep 06;13(9):e1002119
pubmed: 27598345
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):931-5
pubmed: 26699457
Math Biosci. 2012 Apr;236(2):77-96
pubmed: 22387570
PLoS One. 2015 Dec 09;10(12):e0144487
pubmed: 26649422
Int J Mycobacteriol. 2016 Dec;5(4):400-407
pubmed: 27931680
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1044-52
pubmed: 25265362
Lancet Infect Dis. 2018 Aug;18(8):e228-e238
pubmed: 29653698
Nat Genet. 2013 Oct;45(10):1176-82
pubmed: 23995134
BMC Med. 2018 Oct 30;16(1):196
pubmed: 30373589
Int J Tuberc Lung Dis. 2001 Sep;5(9):807-14
pubmed: 11573891
Theor Popul Biol. 1998 Oct;54(2):117-32
pubmed: 9733654
PLoS Pathog. 2009 Jan;5(1):e1000267
pubmed: 19180235
Int J Tuberc Lung Dis. 1998 Feb;2(2):96-104
pubmed: 9562118
Annu Rev Genet. 2001;35:469-99
pubmed: 11700291
Nat Genet. 2002 Dec;32(4):569-77
pubmed: 12457190
BMJ. 2018 Aug 23;362:k2738
pubmed: 30139910
Front Microbiol. 2015 Jun 16;6:612
pubmed: 26136741
Nature. 2013 Oct 10;502(7470):S2-3
pubmed: 24108078
Cell Host Microbe. 2015 Nov 11;18(5):538-48
pubmed: 26607161
Proc Biol Sci. 2009 Mar 22;276(1659):1109-17
pubmed: 19129115
PLoS Pathog. 2011 Mar;7(3):e1001307
pubmed: 21408618
BMC Biol. 2017 Dec 21;15(1):124
pubmed: 29268741
Sci Rep. 2017 Jun 14;7(1):3525
pubmed: 28615641
PLoS Med. 2009 Dec;6(12):e1000199
pubmed: 20027210
Front Immunol. 2015 Jun 29;6:313
pubmed: 26175730
Evolution. 2000 Feb;54(1):51-63
pubmed: 10937183
Tuberculosis (Edinb). 2014 Jan;94(1):55-64
pubmed: 24291066
Nature. 2007 Oct 18;449(7164):843-9
pubmed: 17943121
Nat Rev Drug Discov. 2015 Aug;14(8):511-2
pubmed: 26184493
Proc Biol Sci. 2002 Apr 22;269(1493):867-72
pubmed: 11958720
Immunol Rev. 2015 Mar;264(1):6-24
pubmed: 25703549
Clin Infect Dis. 2000 Sep;31 Suppl 3:S71-4
pubmed: 11010826
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3684-9
pubmed: 11891304
Chest. 2016 Feb;149(2):516-525
pubmed: 26867835
Evolution. 2011 Mar;65(3):842-8
pubmed: 20840594
Infection. 2009 Apr;37(2):80-6
pubmed: 19308318
Nat Med. 1995 Aug;1(8):815-21
pubmed: 7585186
Front Immunol. 2019 Sep 11;10:2139
pubmed: 31572365
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E832-E840
pubmed: 29311321
Clin Chest Med. 1997 Mar;18(1):65-77
pubmed: 9098611
Front Immunol. 2019 Mar 22;10:528
pubmed: 30967867
Philos Trans R Soc Lond B Biol Sci. 2012 Mar 19;367(1590):770-84
pubmed: 22312044
Mol Biol Evol. 2008 Feb;25(2):468-74
pubmed: 18093996
Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):7-14
pubmed: 20049645
Am Rev Respir Dis. 1967 May;95(5):729-45
pubmed: 4960690
Proc Natl Acad Sci U S A. 2016 Aug 9;113(32):9051-6
pubmed: 27457933
Nat Rev Microbiol. 2003 Oct;1(1):17-24
pubmed: 15040176
PLoS One. 2011 Apr 04;6(4):e17601
pubmed: 21483732
R Soc Open Sci. 2018 Aug 22;5(8):180543
pubmed: 30225046
J Infect Dis. 2012 Mar 15;205(6):984-90
pubmed: 22301632
PLoS One. 2018 May 22;13(5):e0195392
pubmed: 29787561

Auteurs

Pere-Joan Cardona (PJ)

Unitat de Tuberculosi Experimental, Institut de Recerca Germans Trias i Pujol (IGTP), Universitat Autònoma de Barcelona, CIBERES, Badalona, Catalonia, Spain. pj.cardona@gmail.com.

Martí Català (M)

Comparative Medicine and Bioimage Centre of Catalonia (CMCiB). Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Catalonia, Spain.

Clara Prats (C)

Escola Superior d'Agricultura de Barcelona, Departament de Física, Universitat Politècnica de Catalunya (UPC)-BarcelonaTech, Castelldefels, Catalonia, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH